Auditory neuropathy (AN) is a condition in which transmission of sound to the brain is abnormal. This is reflected as an electrophysiologic profile of normal otoacoustic emissions (OAE), with abnormal auditory brainstem evoked responses (ABR). Functionally speech perception is impaired and management strategies remain controversial. AN can be missed if high-risk newborns are screened for hearing loss with only OAE testing. The rate of sensorineural hearing loss (SNHL) in high-risk nursery infants is 10 times greater compared with normal term newborns. Therefore, we hypothesize that infants from the neonatal intensive care unit (NICU) are at significantly higher risk for AN than normal term infants.
Introduction
Auditory neuropathy (AN) or auditory dys-synchrony is a pattern of hearing loss, considered to be within the spectrum of sensorineural hearing loss (SNHL) and defined by a profile of absent or severely distorted auditory brainstem responses (ABR) with preserved otoacoustic emissions (OAE) and cochlear microphonics (CM). Acoustic reflexes are also absent. 1 This electrophysiologic profile suggests an abnormality of the hearing apparatus proximal to the outer hair cell that may include the synapses between the cochlear inner hair cells, neurons of the spiral ganglion and the entire auditory nerve. Clinically, the hearing loss is variable with an unsynchronized auditory signal, and often fluctuating with particular difficulty in speech perception in the presence of background noise.
Many of the risk factors associated with AN are the same as for SNHL. These risk factors include positive family history, hyperbilirubinemia, exposure to ototoxic medications, hypoxia, birth asphyxia and intracranial hemorrhages, including intraventricular hemorrhage. [2] [3] [4] [5] [6] [7] The exact anatomical location of abnormality or injury and the pathophysiology of AN are poorly understood. As such, there are no specific risk factors to distinguish AN from cochlear hearing loss.
The overall rate for SNHL in newborns is approximately 3 per 1000. There is a range of prevalence rates reported in neonates, varying from 1 per 1000 for SNHL in normal newborns to 10 per 1000 in neonates from the high-risk nursery. Among children with diagnosed hearing loss, the prevalence rate of AN is high, ranging between 5.1 and 14.6 per 100. 3, [8] [9] [10] There have been case reports since the 1970s of patients presenting with symptoms consistent with AN; however, it was not until 1996 that AN was first defined by Starr et al. 11 Thus, there is a paucity of information regarding prevalence rates of AN among neonates. Berg et al. 12 recently showed that infants in the intensive care nursery are at significantly higher risk for the development of AN. Many of the infants in their nursery had been transported back to the birth hospital and were not included in the study, possibly skewing their data toward an increased AN incidence.
Infants with AN are at high risk for impaired speech and language development. Management protocols are not well defined and require a multidisciplinary approach. Early institution of visual modes of communication is extremely important. Amplification may or may not be of benefit, likely due to the lack of temporal synchrony of signal or to the fluctuating nature of the hearing loss. In selected individuals, cochlear implantation may improve auditory, speech and language outcomes. Unless diagnosed early, infants from the intensive care nursery with AN are at particularly high risk for adverse language and cognitive outcomes.
Given the scarcity of information regarding AN incidence in high-risk neonatal populations, we conducted a comprehensive retrospective cross-sectional case-controlled study to determine the prevalence rate of the AN profile in high-risk infants in Hawaii and to identify those risk factors that may distinguish AN from cochlear hearing loss. We identified infants as high risk if they were admitted to the neonatal intensive care unit (NICU) and we hypothesize that the rate of AN among these infants is significantly higher than that of normal term infants. Infants from the high-risk nursery are screened using the automatic ABR (ALGO 2E; (Natus Medical, San Carlos, CA, USA)). Parameters for the ALGO 2E include a 100 ms click stimulus, alternating polarity, 35 dBnHL, a frequency spectrum of 700 to 1500 Hz, notch filter À12 dB at 60 Hz and À12 dB at 50 Hz, bandpass filter 0.05 to 1.5 kHz (6 dB/octave high pass and 24 dB/octave low pass).
Methods

Patient population
Infants who failed the screening underwent diagnostic ABR (Navigator Pro; Bio-Logic Systems Corp., Mundelein, IL, USA) using the following parameters: 100 ms click stimulus, 33.3 clicks/s repetition tone burst at 27.1/s repetition with Blackman ramp filtering. Responses above 20 dBnHL were considered abnormal. The CM is defined as occurring earlier than wave I with reverse waveform morphology when stimulus polarity is changed from rarefaction to condensation.
Transient evoked OAE or distortion product OAE were used to determine the presence of OAEs. Transient evoked OAE (Otodynamics; Herts, UK) was set using plain click stimuli of 78 to 83 peak equivalent dB sound pressure level (SPL) intensity, duration of 80 ms repeating at 50/s and a response window of 20 ms. Distortion product OAE (Navigator Pro; Bio-Logic Systems Corp., Mundelein, IL, USA) was set at 6 dB emissions above noise floor for 1000 to 6000 Hz. Intensity level was set at 65 dB SPL for band 1 and 55 dB SPL for band 2.
Controls
Control cases were matched for GA and birth weight within the same year of birth in order to minimize changes in care practices over the study period. Demographic data included GA, birth weight and gender. Severity of illness was examined in terms of Apgar scores, length of hospitalization, duration of conventional and high-frequency ventilation, and use of dexamethasone. Common neonatal morbidities including intraventricular hemorrhage, necrotizing enterocolitis, chronic lung disease (CLD) and hydrocephalus were also examined. Specific risk factors for hearing loss were also collected, including congenital cytomegalovirus or congenital toxoplasmosis infection, bacterial meningitis, and exposures to potential ototoxic medications such as vancomycin, aminoglycosides, and furosemide.
Statistics
Associated risk factors for SNHL, AN, and age-matched controls were compared using a one-way ANOVA test performed for continuous variables with Bonferroni post hoc testing for multiple comparisons. Chi Square testing was done for categorical variables with Pearson correlations post hoc. Multivariate analysis was performed to determine interdependence of variables. Values are expressed as means±standard error of the mean. For this analysis, a P-value <0.05 was considered significant. The SPSS 11.5 (SPSS Inc., Chicago, IL, USA) statistical package was used for the analyses.
Results
There were 4250 infants screened for hearing loss from the NICU from 1999 through 2003. We identified 95 cases of hearing loss: 71 with cochlear SNHL and 24 with the AN electrophysiologic profile. From this same cohort, 95 GA-matched controls were identified. In comparison to infants with SNHL, those with AN were significantly smaller, and of younger gestation ( Table 1 ). The ELBW infants (<1000 g birth weight) were at significantly higher risk compared with the other birth weight groups for both AN and SNHL ( Figure 1 ). There were no significant differences in gender distribution between the three groups.
Due to significantly lower birth weight, the infants with AN had longer hospitalizations and greater duration of mechanical ventilation compared to those with SNHL and controls. However, in a sub-analysis of ELBW infants, there was no difference in length of hospitalization between AN, SNHL and control infants. In addition, a significantly greater proportion of AN and SNHL infants were diagnosed with CLD compared with controls.
There were no differences between groups with regard to other neonatal morbidities including intraventricular hemorrhage, necrotizing enterocolitis, hydrocephalus and persistent pulmonary hypertension. Although peak bilirubin levels for infants with SNHL were higher than for controls, there was not a significant difference compared to those with AN (Table 2) . Infants with AN differed from those with SNHL with regard to congenital infections. There were no cases of AN among infants with congenital cytomegalovirus or toxoplasmosis infections. Interestingly, none of the identified three cases of bacterial meningitis developed any hearing loss. 
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Medication exposures are summarized in Table 3 . Infants with AN were more likely to have received aminoglycosides, furosemide or vancomycin compared to infants in the GA-matched control group. Duration of aminoglycoside treatment was longer in infants who developed AN vs SNHL or controls. More infants with AN and SNHL were exposed to dexamethasone compared to controls, but dexamethasone exposure did not correlate with an increase in AN compared with SNHL.
Discussion
In the present study, 95 (2.1%) of all infants admitted to the KMCWC NICU over a 5-year period developed hearing loss. Of these infants, 24 (25.3%) demonstrated the AN electrophysiologic profile. Two-thirds (62.5%) of the infants with the AN profile were ELBW, compared with 28.2% of infants with SNHL, suggesting that there is a much greater risk for AN in the smallest, most premature infants. Among the population of ELBW infants, the prevalence rates of AN and SNHL were nearly equivalent (4.9 and 5.6 per 100 ELBW infants, respectively). This is in contrast to the larger infants who have a 4 to 8 times greater occurrence of SNHL than AN.
The first historical report of AN was in 1979, 13 but it was not defined as a clinical disorder until 1996. Since that time, there have been few reports on prevalence rates of AN within the pediatric population. One study of a large population of Australian infants and children at risk for hearing loss 3 reported 12 children with AN out of 109 with confirmed SNHL, an 11% prevalence. A subsequent study from the US reported a prevalence rate of 5.1% in a population of children with hearing loss. 8 Although the rate of SNHL in the NICU infant population is 10 times more common than for normal term infants, the prevalence of AN in this same population is not established. Stein 14 reported an occurrence of AN of 4 per 100 in a consecutive series of admissions to an infant special care nursery. More recently Berg et al.
12 reported a 24.1% prevalence of AN from a selected group of NICU infants.
Reported risk factors for AN are the same as for SNHL, including hyperbilirubinemia, hypoxia, exposure to ototoxic medications and a positive family history. At present, there are no distinguishing risk factors specific to one condition vs the other.
Past case reports suggest an association between neonatal hyperbilirubinemia and the development of AN. 8, 3, 15 Bilirubin is a known neuronal toxin, and it may play a role in the etiology of AN. [16] [17] [18] [19] In a recent study, Berg et al. 12 reported an association between AN and elevated peak total bilirubin levels. However, total bilirubin levels are difficult to interpret in the absence of additional metabolic and nutritional information, especially since bilirubin bound to albumin does not cross the blood-brain barrier. Free bilirubin more accurately reflects the potential toxicity, but it cannot be measured in the clinical setting. In this study, there was an association between peak bilirubin and SNHL, but no significant association with AN.
According to the Joint Committee on Infant Hearing year 2000 position statement, admission to an NICU for at least 48 h is a significant risk factor for hearing loss. 20 These infants are exposed to several modalities of treatment and experience specific morbidities that place them at high risk for hearing loss. As a group, infants with SNHL and AN had significantly longer hospital stays than their age matched controls. However, the occurrence of specific neonatal morbidities like intraventricular hemorrhage, hydrocephalus and necrotizing enterocolitis were no different. In addition, length of stay was longer for those with AN compared to those with SNHL. Although this may be due to the lower mean birth weight of AN infants, sub-group analysis of ELBW infants did not show any differences between the three groups.
CLD, or BPD, is the one morbidity that was significantly correlated with AN and SNHL, with a greater percentage in infants with AN. Duration of mechanical ventilation was also greater in these infants. Taken together this may reflect a greater degree of morbidity. However, the use of high-frequency ventilation, often used in infants with severe respiratory illness, correlated with the development of SNHL but not with AN.
Another marker of severe respiratory illness in the NICU population has been the use of dexamethasone. More recently, postnatal dexamethasone exposure has been correlated with the development of cerebral palsy. [21] [22] [23] [24] [25] In this study, infants with AN and SNHL were more likely to be exposed to dexamethasone than controls; however, this was not independent of the diagnosis of CLD.
Exposure to potentially ototoxic medications is another risk factor for many NICU infants. For this population, aminoglycosides, vancomycin and furosemide are among the most commonly administered medications. While the use of aminoglycosides has long been associated with cochlear hearing loss, it has also been reported to be a risk factor for AN; however, the mechanism for this effect is not known. 8, 12, 14 In the present study, exposure to aminoglycosides was positively correlated with both SNHL and AN. In addition, those infants with AN had a significantly longer exposure to aminoglycosides compared to those with SNHL or controls.
The loop diuretic furosemide, an inhibitor of the Na-K-2Cl cotransporter, is known to cause hearing loss due to changes in endolymph composition. 26 Alteration in endolymph electrolyte composition combined with the inhibition of cell proliferation 27 may contribute to permanent structural changes within the inner ear of the developing neonate after loop diuretic exposure. Over the past two decades, there have been conflicting reports regarding the association between furosemide and SNHL in high-risk neonates. 7, 28, 29 Results from the current study associate exposure to furosemide with both SNHL and AN. Multivariate analysis suggests that this association is independent of exposure to aminoglycosides, vancomycin and dexamethasone.
In summary, the present study supports the notion that ELBW infants are at high risk for developing AN. Compared to those diagnosed with SNHL, infants with the AN profile were more premature and had lower birth weights. Although many of the risk factors are the same, infants with the AN profile experienced longer hospitalizations, more mechanical ventilation and were more likely to be diagnosed with CLD compared to those with SNHL. In addition, these infants with the AN profile had more exposure to furosemide, vancomycin, aminoglycosides and dexamethasone. These exposures may be primarily involved with the development of AN or indicators of the degree of illness in this fragile population. Long-term follow-up, beyond the scope of this study, is needed to determine if the electrophysiologic findings and hearing outcomes change with maturity in these preterm infants.
At present, little is known about the pathophysiology of AN. Earlier diagnosis during infancy will help to advance our understanding of etiology and natural history of the condition. This can then lead to better therapeutic approaches, as treatment strategies for AN are presently no different than those for SNHL, 30 yet the lack of temporal synchrony and the fluctuating losses experienced by these individuals may lessen the effectiveness of amplification devices and potentially place them at risk for noise-induced trauma. 11 The diagnosis will be missed if these high-risk infants are screened by OAE alone. In addition, an initially normal OAE may become abnormal over time, 31 which will interfere with accurate and early identification. Thus, all infants from the NICU should be screened by automated ABR, and an abnormal result should prompt evaluation for AN before discharge. Long-term follow-up is necessary to determine the natural history of AN in these immature infants.
